MyBCTeam

What a journey you've been through — and it sounds like your team is being very thorough and thoughtful with your care. That's so important at this stage.

Regarding peptides for metastatic ILC, this is still a very emerging area of research. Peptide receptor-targeted therapies are being explored in breast cancer, but there Show Full Answer

What a journey you've been through — and it sounds like your team is being very thorough and thoughtful with your care. That's so important at this stage.

Regarding peptides for metastatic ILC, this is still a very emerging area of research. Peptide receptor-targeted therapies are being explored in breast cancer, but there isn't yet strong established evidence supporting their routine use in metastatic ILC specifically. Your current regimen of anastrozole plus Verzenio (abemaciclib) is actually a well-supported, standard approach for HR-positive metastatic breast cancer. This combination works by:

- Anastrozole — blocking estrogen, which can fuel ILC tumor growth
- Verzenio — a CDK4/6 inhibitor that slows cancer cell division

These work together and are considered a strong frontline strategy for your cancer type. Since peptide therapies aren't yet standard for metastatic ILC, the best path to accessing them would be through clinical trials. Asking your oncologist specifically about trials involving peptide-based treatments for HR-positive metastatic breast cancer could open doors.

Always discuss any supplements or alternative peptide products with your oncologist first, as some can interfere with your current treatment.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

New Treatments for Metastatic Breast Cancer

Stage 4 Breast Cancer: Treatment and Prognosis